Literature DB >> 17493878

Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life.

Christian G Bien1, Christian E Elger.   

Abstract

Limbic encephalitis (LE) was described in the 1960s as a clinical-pathological syndrome in adults. Initially, the paraneoplastic form was the center of interest. An increasing number of diagnostically valuable autoantibodies in patients' sera (and cerebrospinal fluid) have been identified. Lately, the impact of non-paraneoplastic LE cases has been acknowledged. In the serum of some of these patients, antibodies against voltage-dependent potassium channels (VGKC antibodies) have been detected. The characteristic MRI course of LE patients has recently been described in detail: hippocampal swelling and T2/FLAIR signal increase are early findings. After a few months, the swelling regresses, followed by hippocampal atrophy with continuous signal increase. A general consensus on formal diagnostic criteria for all LE subsyndromes has not yet been reached. This article proposes such diagnostic criteria and formulates suggestions for treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493878     DOI: 10.1016/j.yebeh.2007.03.011

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  27 in total

1.  Lacosamide for epileptic seizures in patients with co-morbidities and unusual presentations of epilepsy.

Authors:  Alba Sierra-Marcos; Pedro Emilio Bermejo; Raquel Manso Calderón; Angela María Gutiérrez-Álvarez; Catalina Jiménez Corral; Daniel Sagarra Mur
Journal:  CNS Drugs       Date:  2011-12-05       Impact factor: 5.749

Review 2.  Autoimmune-mediated encephalitis.

Authors:  Philippe Demaerel; Wim Van Dessel; Wim Van Paesschen; Rik Vandenberghe; Koen Van Laere; Jennifer Linn
Journal:  Neuroradiology       Date:  2011-01-27       Impact factor: 2.804

Review 3.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

Review 4.  Antibodies in epilepsy.

Authors:  Cynthia M Correll
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

5.  Perisylvian vulnerability to postencephalitic epilepsy.

Authors:  Claude Steriade; Lara Jehi; Balu Krishnan; Marcia Morita-Sherman; Ahsan N V Moosa; Stephen Hantus; Patrick Chauvel
Journal:  Clin Neurophysiol       Date:  2020-05-11       Impact factor: 3.708

6.  Volumetry of Mesiotemporal Structures Reflects Serostatus in Patients with Limbic Encephalitis.

Authors:  L Ernst; B David; J Gaubatz; I Domínguez-Narciso; G Lüchters; A J Becker; B Weber; E Hattingen; C E Elger; T Rüber
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

7.  Autoimmune epilepsy: clinical characteristics and response to immunotherapy.

Authors:  Amy M L Quek; Jeffrey W Britton; Andrew McKeon; Elson So; Vanda A Lennon; Cheolsu Shin; Christopher Klein; Robert E Watson; Amy L Kotsenas; Terrence D Lagerlund; Gregory D Cascino; Gregory A Worrell; Elaine C Wirrell; Katherine C Nickels; Allen J Aksamit; Katherine H Noe; Sean J Pittock
Journal:  Arch Neurol       Date:  2012-05

8.  The effect of delayed anti-NMDAR encephalitis recognition on disease outcome.

Authors:  Vlatko Sulentic; Zeljka Petelin Gadze; Filip Derke; Marija Santini; Danira Bazadona; Sibila Nankovic
Journal:  J Neurovirol       Date:  2018-05-21       Impact factor: 2.643

9.  [Immune-mediated epilepsy and encephalopathy].

Authors:  C Kramme; C G Bien
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

10.  MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis.

Authors:  A L Kotsenas; R E Watson; S J Pittock; J W Britton; S L Hoye; A M L Quek; C Shin; C J Klein
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-18       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.